Safety and Activity of the Immune Modulator HE2000 on the Incidence of Tuberculosis and Other Opportunistic Infections in AIDS Patients

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2007 May 2

PMID 17470653

Citations 12

Authors

Dwight R Stickney

Zoja Noveljic

Armando Garsd

Daniel A Destiche

James M Frincke

Affiliations

Soon will be listed here.

Abstract

Twenty-five AIDS patients were treated with HE2000, a synthetic adrenal hormone. The drug was well tolerated and safe and reduced both the incidence of tuberculosis coinfection by 42.2% (P < 0.05) and the cumulative incidence of opportunistic infections (P < 0.05). These results warrant further clinical investigation of HE2000.

Citing Articles

: A HERV Turn-On for Autoimmunity, Neurodegeneration, and Cancer?.

Dow C, Pierce E, Sechi L Microorganisms. 2024; 12(9).

PMID: 39338563 PMC: 11434025. DOI: 10.3390/microorganisms12091890.

The Immunoregulatory Actions of DHEA in Tuberculosis, A Tool for Therapeutic Intervention?.

Bongiovanni B, Diaz A, Santucci N, DAttilio L, Bottasso O, Hernandez Pando R Front Endocrinol (Lausanne). 2022; 13:892270.

PMID: 35733782 PMC: 9207529. DOI: 10.3389/fendo.2022.892270.

16α-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis co-morbidity treatment.

Lopez-Torres M, Marquina-Castillo B, Ramos-Espinosa O, Mata-Espinosa D, Barrios-Payan J, Baay-Guzman G Clin Exp Immunol. 2021; 205(2):232-245.

PMID: 33866550 PMC: 8274213. DOI: 10.1111/cei.13603.

[Comparative analysis of clinical features of primary and secondary laryngeal tuberculosis].

Ai Y, Liu H, Xu H, Liu Y, Li L Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021; 35(1):38-41.

PMID: 33540970 PMC: 10128529. DOI: 10.13201/j.issn.2096-7993.2021.01.009.

Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from .

Naciuk F, Faria J, Goncalves Eufrasio A, Cordeiro A, Bruder M ACS Med Chem Lett. 2020; 11(6):1250-1256.

PMID: 32551008 PMC: 7294730. DOI: 10.1021/acsmedchemlett.0c00106.

References

Siegal F, Kadowaki N, Shodell M, Shah K, Ho S, Antonenko S . The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999; 284(5421):1835-7. DOI: 10.1126/science.284.5421.1835. View

Freilich D, Ferris S, Wallace M, Leach L, Kallen A, Frincke J . 16alpha-bromoepiandrosterone, a dehydroepiandrosterone (DHEA) analogue, inhibits Plasmodium falciparum and Plasmodium berghei growth. Am J Trop Med Hyg. 2001; 63(5-6):280-3. View

Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L . Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood. 2001; 98(4):906-12. DOI: 10.1182/blood.v98.4.906. View

Feldman S, Stein D, Amrute S, Denny T, Garcia Z, Kloser P . Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol. 2001; 101(2):201-10. DOI: 10.1006/clim.2001.5111. View

Ayi K, Giribaldi G, Skorokhod A, Schwarzer E, Prendergast P, Arese P . 16alpha-bromoepiandrosterone, an antimalarial analogue of the hormone dehydroepiandrosterone, enhances phagocytosis of ring stage parasitized erythrocytes: a novel mechanism for antimalarial activity. Antimicrob Agents Chemother. 2002; 46(10):3180-4. PMC: 128802. DOI: 10.1128/AAC.46.10.3180-3184.2002. View

Pedersen N, North T, Rigg R, Reading C, Higgins J, Leutenegger C . 16alpha-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression. Vet Immunol Immunopathol. 2003; 94(3-4):133-48. DOI: 10.1016/s0165-2427(03)00081-3. View

. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19. View

Hernandez-Pando R, Aguilar-Leon D, Orozco H, Serrano A, Ahlem C, Trauger R . 16alpha-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis. J Infect Dis. 2004; 191(2):299-306. DOI: 10.1086/426453. View

Reading C, Dowding C, Schramm B, Garsd A, Onizuka-Handa N, Stickney D . Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000). Clin Microbiol Infect. 2006; 12(11):1082-8. DOI: 10.1111/j.1469-0691.2006.01520.x. View

10.

Frincke J, Stickney D, Onizuka-Handa N, Garsd A, Reading C, Krudsood S . Reduction of parasite levels in patients with uncomplicated malaria by treatment with HE2000. Am J Trop Med Hyg. 2007; 76(2):232-6. View

11.

Siegal F, Lopez C, FITZGERALD P, Shah K, Baron P, Leiderman I . Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity. J Clin Invest. 1986; 78(1):115-23. PMC: 329539. DOI: 10.1172/JCI112539. View

12.

Ferbas J, Navratil J, Logar A, Rinaldo C . Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV-1 infection. Clin Diagn Lab Immunol. 1995; 2(2):138-42. PMC: 170116. DOI: 10.1128/cdli.2.2.138-142.1995. View

13.

Lin H, Pedneault L, Hollinger F . Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1998; 36(3):835-9. PMC: 104640. DOI: 10.1128/JCM.36.3.835-839.1998. View